Genomate Health, Cambridge, MA (2026)

03/13/2026

Cancer has a way of taking over everything: your time, your attention, your conversations, your plans. But behind every diagnosis is still your life, your family, and the moments that matter most.

The Genomate Second Opinion Service was created to help you make treatment decisions with greater clarity, so cancer doesn’t have to define every choice you make.

By combining molecular expertise, advanced computational analysis, and the clinical judgment of a licensed oncologist, we look deeper into the biology of your cancer and review the treatment options that may make sense for your specific case. You’ll meet with an oncologist who walks you through the analysis and provides a clear written report you can revisit or share with your care team.

Because the goal isn’t just another opinion.

It’s the reassurance that your decision was made with the fullest understanding possible, so you can spend less time worrying and more time focusing on the people and moments that truly matter.

Learn more:
https://www.genomate.health/services/second-opinion

03/11/2026

Most cancer treatment decisions are made under enormous pressure.

Patients and families are asked to choose a path forward while facing uncertainty, complex data, and limited time. And often while wondering: “𝐀𝐦 𝐈 𝐠𝐞𝐭𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭?”

At Genomate Health, we believe you deserve the chance to understand your cancer as deeply as possible before making those decisions. That’s why we’re launching the Genomate Second Opinion Service.

This service brings together three layers of expertise:
1️⃣ Molecular genetics experts who carefully review your existing NGS results
2️⃣ Genomate’s computational reasoning platform, which analyzes cancer as a connected biological system
3️⃣ A licensed oncologist, who reviews the full analysis and delivers a personalized medical second opinion

Here’s what you receive:
✔️ A deep analysis of your cancer, not just individual mutations, but how the tumor works as a system
✔️ Independent review by molecular experts and a licensed oncologist
✔️ A telehealth consultation where the oncologist walks through what was considered and why
✔️ A clear written report you can share with your care team to support next steps. It explains the treatment options evaluated, the clinical reasoning behind them, and the supporting scientific evidence.

Because when facing cancer, you deserve to move forward knowing every option has been carefully considered.

Learn more about the Genomate Second Opinion Service:
https://www.genomate.health/services/second-opinion

03/09/2026

Every cancer diagnosis begins with uncertainty.
For many patients with kidney cancer, the questions come quickly:
What does this mean for me?
Which treatment is the right one?
Do we truly understand my cancer?

The reality is that no two kidney cancers are the same. Behind the diagnosis lies a complex molecular story that can shape how a tumor behaves and how it may respond to treatment.

On World Kidney Day, and during Kidney Cancer Awareness Month, we are reminded that better decisions in cancer care start with better understanding.

At Genomate Health, we help uncover the full molecular complexity of each patient’s cancer using computational reasoning, turning vast molecular data into insights that can support more informed treatment choices.

Because for every patient facing cancer, clarity matters.
And every patient deserves a treatment strategy built on the complete picture of their disease.

03/04/2026

Our team at Genomate Health works every day to support better cancer treatment decisions through computational reasoning.

But one of the most powerful tools against cancer isn’t treatment, it’s prevention.

Today, on HPV Awareness Day, we’re reminded that many cancers can be prevented through vaccination, screening, and awareness. HPV is responsible for nearly all cervical cancers and a growing number of other cancers. Yet millions of people around the world still lack access to the information, prevention, and care that could significantly reduce their risk.

As a team working in precision oncology, we see firsthand how important earlier action can be. Preventing cancer, or detecting it early, changes everything for patients.

Today we stand with clinicians, researchers, and public health advocates working to reduce HPV-related cancers and protect future generations.

Because the best cancer to treat is the one that never develops.

02/28/2026

Rare diseases challenge medicine in a different way.

Fewer cases mean fewer studies. Less consensus. More uncertainty. And for patients, that uncertainty can delay answers and limit options.

At Genomate Health, this is exactly where structured, evidence-based reasoning matters most. Our computational reasoning approach does not rely on frequency. It evaluates the full molecular profile of a tumor, aggregates available evidence, and prioritizes therapies based on biological relevance. That matters especially in rare cancers, where clinical experience may be limited and every decision carries weight.

On , we reaffirm our commitment to making precision oncology work not only for the many, but also for the few.

Because rare diseases are not rare for the people living with them.

02/16/2026

When a child is diagnosed with cancer, everything changes. For the family. For the care team. And for those working behind the scenes to help find the best possible path forward.

At Genomate Health, we think about the young patients whose molecular profiles we review. A name. An age. A life just beginning. A child whose doctors are searching for clarity in the face of complexity.

That responsibility shapes how we work. It drives our rigor. It demands precision. It reminds us that behind every dataset is a future that deserves protecting.

Today, we stand with children and families navigating the unimaginable. And we recommit to doing our part, so that every child facing cancer has the strongest, most informed care possible behind them.

02/11/2026

February 11 is the International Day of Women and Girls in Science, a reminder that the future of science depends on who gets to shape it.

At Genomate Health, more than half of our team is women.
They lead research that untangles molecular complexity.
They design tools that help oncologists act with clarity.
They manage systems, build technology, and shape our strategy.
Their work isn’t just essential to our mission, it defines how we deliver on it.

We believe that real innovation in precision oncology requires many perspectives at the table. Equity isn’t a tagline. It’s what makes science stronger, more honest, and more useful to the people it serves.

To our colleagues, and to all women across STEM: thank you 💚

Learn more about the women working at Genomate Health: https://www.genomate.health/news-article/celebrating-women-in-science

02/06/2026

What if molecular complexity wasn’t a barrier, but a roadmap?

At the upcoming AAAS Annual Meeting, our Founder and CSO, Istvan Petak MD, PhD, will explore how computational reasoning can help oncologists and researchers translate genomic data into therapy decisions that actually work.

Why does it matter?
Because most tumors don’t follow textbook rules. And matching a patient to the right targeted therapy or trial often means navigating dozens of biomarkers, resistance pathways, and conflicting evidence.

If you're working to bring more precision, consistency, or equity to cancer care, this is a conversation you don't want to miss: https://aaas.confex.com/aaas/2026/meetingapp.cgi/Paper/35453

02/03/2026

Cancer doesn’t play fair. But it can be outplayed.

This , we’re reminded that cancer adapts. It learns. It finds workarounds.

That’s why we need smarter tools, not just to keep up, but to think ahead.

At Genomate Health, we use computational reasoning to help oncologists see the full board. Our platform analyzes complex tumor profiles and highlights evidence-based treatments, so clinicians can make confident, strategic moves, even in the toughest cases.

Because beating cancer takes more than new therapies.
It takes clarity, foresight, and the ability to plan three steps ahead.

01/28/2026

We’re proud to see our story featured in Telex.hu highlighting how Hungarian innovation is shaping the future of cancer care on the global stage: https://telex.hu/g7/adat/2026/01/28/oncompass-petak-istvan-genomate-budapest-boston-rakdiagnosztika

Both Genomate Health and Oncompass Medicine started with a bold vision: to understand each tumor at the molecular level and help clinicians make more informed, personalized treatment decisions. Today, that vision continues as a united, international company serving patients and clinicians across Europe and the US.

01/28/2026

How can we turn complex tumor profiles into clear, evidence-based treatment decisions?

On January 30, Genomate Health Founder and CSO Istvan Petak MD, PhD will speak at the Center for Cancer Research Impromptu Seminar Series, hosted by Gergely Szakacs, to explore this question and more.

Join us to learn how structured, algorithmic tools are helping improve consistency, confidence, and outcomes in precision oncology.

Sign up here: https://lnkd.in/dQmsreTp

01/22/2026

Cervical cancer is one of the most preventable and treatable cancers, if caught early. Screening, HPV vaccination, and timely care have changed the outlook for millions. But progress isn’t equal everywhere.

Too many people are still diagnosed late. Too many face barriers to testing or lack access to care tailored to the biology of their cancer. At Genomate Health, we focus on the moments after diagnosis, helping oncologists make evidence-based treatment decisions, especially when standard options fall short.

This month, we stand with the clinicians, researchers, and advocates working to ensure everyone has access to the tools to eliminate cervical cancer.

Genomate Health

03/13/2026

03/11/2026

03/09/2026

03/04/2026

02/28/2026

02/16/2026

02/11/2026

02/06/2026

02/03/2026

01/28/2026

01/28/2026

01/22/2026

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category